Gupta Neil, Kabahizi Jules, Mukabatsinda Constance, Walker Timothy David, Musabeyezu Emmanuel, Kiromera Athanase, Van Nuil Jennifer Ilo, Steiner Kevin, Mukherjee Joia, Nsanzimana Sabin, Mbituyumuremyi Aimable
Division of Global Health Equity, Brigham & Women's Hospital, Boston, Massachusetts, United States of America.
Partners In Health / Inshuti Mu Buzima, Rwinkwavu, Rwanda.
PLoS One. 2017 Mar 21;12(3):e0174148. doi: 10.1371/journal.pone.0174148. eCollection 2017.
Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background and characteristics of a national cohort of patients with HCV infection enrolled in care and awaiting therapy with DAAs.
We conducted a retrospective chart review of all adult patients with confirmed HCV infection who were currently enrolled in care and treatment at the four existing hepatitis referral centers in Rwanda. Patient charts at these centers were reviewed, and routinely collected data were recorded and analyzed. Overall, 253 patients were identified; median age was 56 years (IQR: 43, 65), and 149 (58.9%) were female. Median viral load was 688,736 IU/ml and 96.7% were HCV genotype 4. As classified by FIB-4 score, 64.8% of the patients had moderate to severe fibrosis. Fibrosis stage was associated with age (OR 1.12, CI 1.09-1.17), but not with time since diagnosis, gender, treatment center, or type of insurance. There was a low frequency of documented co-morbid conditions, including hypertension, diabetes, HIV, and hepatitis B virus.
Compared to an estimated 55,000 patients eligible for HCV treatment in Rwanda, this study identified only 253 patients currently diagnosed and engaged in care, highlighting an immense treatment gap in HCV, likely due to the lack of accessible and affordable screening, diagnostic, and treatment modalities. The patients that were enrolled in care had a disproportionately advanced fibrosis stage, possibly indicating late presentation to care or lack of treatment options. In the context of newly available and effective treatment options, this study supports the overall need to accelerate access to HCV screening, diagnostics, and care and treatment services in resource-limited settings in sub-Saharan Africa.
撒哈拉以南非洲地区丙型肝炎病毒(HCV)的治疗途径极为有限。随着直接抗病毒药物(DAAs)的出现,全球市场上现已具备高效且易于给药的口服治疗方案。本研究旨在了解纳入治疗并等待使用DAAs治疗的全国HCV感染患者队列的背景和特征。
我们对卢旺达现有的四家肝炎转诊中心目前正在接受护理和治疗的所有确诊HCV感染成年患者进行了回顾性病历审查。对这些中心的患者病历进行了审查,并记录和分析了常规收集的数据。总体而言,共识别出253例患者;中位年龄为56岁(四分位间距:43,65),149例(58.9%)为女性。中位病毒载量为688,736 IU/ml,96.7%为HCV基因4型。根据FIB-4评分分类,64.8%的患者有中度至重度纤维化。纤维化阶段与年龄相关(比值比1.12,可信区间1.09 - 1.17),但与诊断后的时间、性别、治疗中心或保险类型无关。记录在案的合并症发生率较低,包括高血压、糖尿病、HIV和乙型肝炎病毒。
与卢旺达估计55,000名符合HCV治疗条件的患者相比,本研究仅识别出253例目前已确诊并接受护理的患者,凸显了HCV治疗方面的巨大差距,这可能是由于缺乏可及且负担得起的筛查、诊断和治疗方式所致。接受护理的患者纤维化阶段严重程度不成比例,这可能表明就诊延迟或缺乏治疗选择。在有新的有效治疗选择的背景下,本研究支持在撒哈拉以南非洲资源有限的环境中加速获取HCV筛查、诊断以及护理和治疗服务的总体需求。